Torkinib

Torkinib (PP 242) 是一种选择性,ATP 竞争型的mTOR 抑制剂,IC50为 8 nM。它也抑制mTORC1和mTORC2,IC50分别为 30 nM 和 58 nM。

CAS号

1092351-67-1

分子式

C16H16N6O

主要靶点

Mitophagy|Autophagy|PI3K|Apoptosis|mTOR

仅限科研使用

Cat No : CM05230

Print datasheet

Synonyms

PP 242



产品信息

Torkinib (PP 242) is a selective and ATP-competitive mTOR inhibitor (IC50: 8 nM). It also inhibits mTORC1/2 (IC50s: 30/58 nM).

CAS号 1092351-67-1
分子式 C16H16N6O
主要靶点 Mitophagy|Autophagy|PI3K|Apoptosis|mTOR
主要通路 PI3K/Akt/mTOR信号通路|凋亡|自噬
分子量 308.34
纯度 99.23%, 此纯度可做参考,具体纯度与批次有关系,可咨询客服
储存条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year
别名 PP 242

靶点活性

p110δ:0.10 μM (cell free)|mTOR:8 nM (cell free)|mTORC1:30 nM (cell free)|mTORC2:58 nM (cell free)

体内活性

In mouse p190 model, short-term oral dosing with PP242 in a dose-dependent manner significantly reduced leukemic burden in the spleen and bone marrow. In a long-term survival study, oral dosing of PP242 (30 and 60 mg/kg) significantly delayed the onset of leukemia [2]. In fat and liver, PP242 was able to completely inhibit the phosphorylation of Akt at S473 and T308. Surprisingly, PP242 was only partially able to inhibit the phosphorylation of Akt in skeletal muscle and was more effective at inhibiting the phosphorylation of T308 than S473, despite it's ability to fully inhibit the phosphorylation of 4EBP1 and S6 [3].

体外活性

Torkinib (PP242) potently inhibited mTOR (IC50: 8 nM) but was much less active against other PI3-K family members. Testing of this compound against 219 protein kinases revealed remarkable selectivity relative to the protein kinome. In BT549 cells, PP242 inhibited the phosphorylation of Akt, the mTOR substrate p70S6K, and its downstream target S6 [1]. PP242 suppressed growth by > 90%, with low nanomolar potency (GI50: 12 nM). PP242 had greater anti-proliferative potency relative to rapamycin in a panel of solid tumor cell lines carrying either PI3K gain-of-function or PTEN loss-of-function [2].

溶解度

DMSO:7.7 mg/mL (25 mM)

细胞实验

Cells were seeded in triplicate wells of 96-well flat bottom culture plates for 48 hr in the presence of increasing concentrations of indicated inhibitors. Cell viability and median-effect dose affecting growth (GIC50) was determined using the MTS assay. Absorbance values (490 nm) were normalized to controls and expressed as %MTS conversion. Wells lacking cells but with MTS added was used as the zero value when normalizing. For drug combination experiments, a range of fixed ratios of inhibitors was used to assess synergy using the combination index (CI) with CalcuSyn software according to the median-effect method as previously described. For proliferation experiments with PC-3, SKOV3, 786-O, and U87 cells, the CellTiter-Glo Luminescent reagent was used following the manufacturer's instructions. Quantitation was performed as mentioned above [2].

动物实验

Drugs were prepared in 100 μl of vehicle containing 20% DMSO, 40% PEG-400, and 40% saline. Six-wk-old male C57BL/6 mice were fasted overnight prior to drug treatment. PP242 (0.4 mg), rapamycin (0.1 mg), or vehicle alone was injected IP. After 30 min for the rapamycin-treated mouse or 10 min for the PP242 and vehicle-treated mice, 250 mU of insulin in 100 μl of saline was injected IP. 15 min after the insulin injection, the mice were killed by CO2 asphyxiation followed by cervical dislocation. Tissues were harvested and frozen on liquid nitrogen in 200 μl of cap lysis buffer. The frozen tissue was thawed on ice, manually disrupted with a mortar and pestle, and then further processed with a micro tissue-homogenizer. The protein concentration of the cleared lysate was measured by Bradford assay and 5–10 μg of protein was analyzed by Western blot as described above [3].

参考文献

1.Apsel B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
2.Janes MR, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010 Feb;16(2):205-13.
3.Feldman ME, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009 Feb 10;7(2):e38.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2